Common blood pressure drugs can reduce inflammation in liver disease

Credit: Unsplash+

Chronic liver damage is a severe condition that can lead to liver tissue scarring, ultimately causing increased blood pressure in the gastrointestinal tract’s vascular system, a condition known as portal hypertension.

This can result in significant complications. However, a recent study conducted by MedUni Vienna has unveiled a potential breakthrough.

It suggests that commonly prescribed high blood pressure drugs called beta-blockers possess anti-inflammatory properties when used in advanced liver disease.

While beta-blockers have long been used as standard treatment, only a portion of patients typically experiences a clinically relevant reduction in portal vein pressure.

Beta-Blockers and Systemic Inflammation

This recent study has unearthed a new facet of beta-blockers: their impact on systemic inflammation, which refers to inflammation throughout the entire body.

The research team identified biomarkers of systemic inflammation both before and during beta-blocker treatment.

Remarkably, patients in advanced stages of cirrhosis, a consequence of chronic liver damage, exhibited not only a higher likelihood of experiencing systemic inflammation but also a greater likelihood of benefiting from beta-blockers’ anti-inflammatory effects.

Positive Outcomes in Cirrhotic Patients

The cirrhotic patients in the study displayed a reduction in inflammatory markers, such as white blood cell count, during beta-blocker therapy.

Moreover, they experienced fewer complications associated with portal hypertension and a reduced risk of death.

Importantly, the study established a correlation between the increasing severity of portal hypertension and inflammatory reactions in the body.

This suggests that beta-blockers could play a pivotal role in reducing inflammation and improving outcomes for individuals grappling with advanced liver disease.

Implications and Future Prospects

The researchers contend that, pending further validation in clinical trials, these findings could enhance the accuracy of predicting the benefits of beta-blocker treatment, providing patients with optimal advice.

This study underscores the potential advantages of beta-blockers for individuals facing advanced liver disease, contributing to the growing body of evidence supporting their use.

Additionally, it underscores the significance of comprehending the intricate interactions between different bodily systems and their potential impact on disease progression and treatment outcomes.

A Word of Caution

As always, patients should engage in open discussions with their healthcare providers before initiating or discontinuing any medication. Individual circumstances and medical histories may significantly influence treatment decisions.


In conclusion, beta-blockers have shown promise in reducing inflammation in advanced liver disease, potentially offering new avenues for treatment and improved outcomes.

This study represents a significant step forward in the quest to address the complexities of liver disease and its systemic implications.

However, further research and clinical validation are necessary to fully realize the potential benefits of beta-blockers in this context.

Patients and healthcare providers alike should remain vigilant in exploring treatment options that may enhance the quality of care for individuals with advanced liver disease.

If you care about high blood pressure, please read studies about the ideal blood pressure for older people, and widely-used blood pressure drugs linked to bowel diseases.

For more information about high blood pressure, please see recent studies about high blood pressure drugs that may cause memory problem, and 12 foods that lower blood pressure.

Follow us on Twitter for more articles about this topic.

Copyright © 2023 Knowridge Science Report. All rights reserved.